GlycoMark Receives More than $240,000 to Advance Blood Test for Diabetes and Pre-Diabetes

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--GlycoMark, a research and development company for diabetes testing, has been awarded $244,479 to advance the company’s innovative early detection algorithm for diabetes and pre-diabetes, which combines the hemoglobin A1c (HbA1c) and 1,5-anhydroglucitol (GlycoMark) blood tests. The company received the maximum allowable amount under the Qualifying Therapeutic Discovery Project (QTDP), part of the Patient Protection and Affordable Care Act of 2010.